Literature DB >> 28905638

Higher Risk of Bleeding in Asians Presenting With ST-Segment Elevation Myocardial Infarction: Analysis of the National Inpatient Sample Database.

Naoki Misumida1, Gbolahan O Ogunbayo1, Sun Moon Kim1, Odunayo Olorunfemi2, Ayman Elbadawi2, Richard J Charnigo3,4, Ahmed Abdel-Latif1, Khaled M Ziada1.   

Abstract

Bleeding is a major complication in patients presenting with ST-segment elevation myocardial infarction (STEMI). Several studies suggested that Asians are more susceptible to bleeding when treated with antiplatelets, anticoagulants, and thrombolytic agents. In our study, we aimed to investigate the association between Asian ethnicity and bleeding events in patients who presented with STEMI. We analyzed the Nationwide Inpatient Sample database from 2002 to 2013 and identified patients hospitalized with a primary diagnosis of STEMI. We compared clinical outcomes between patients of Asian and white ethnicity. Primary outcome was inhospital major bleeding defined as a composite of intracranial hemorrhage and blood transfusions for bleeding events. After exclusions, an estimated 1 695 680 white and 46 563 Asian patients with STEMI were included in the analysis. Asian patients had a higher incidence of inhospital major bleeding (3.6% vs 2.2%, P < .001) without a significant difference in inhospital mortality (9.3% vs 8.7%, P = .06). Asian ethnicity was an independent predictor for major bleeding (estimated odds ratio: 1.32; 95% confidence interval: 1.16-1.51; P < .001). This increased risk of bleeding would warrant further investigation of optimal treatment strategies tailored for patients with STEMI of Asian ethnicity.

Entities:  

Keywords:  Asian; acute ST-segment elevation myocardial infarction; bleeding; complications; primary percutaneous coronary intervention

Mesh:

Substances:

Year:  2017        PMID: 28905638     DOI: 10.1177/0003319717730168

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  5 in total

1.  Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific Consensus Group.

Authors:  Ae-Young Her; Eun-Seok Shin; Liew Houng Bang; Amin Ariff Nuruddin; Qiang Tang; I-Chang Hsieh; Jung-Cheng Hsu; Ong Tiong Kiam; ChunGuang Qiu; Jie Qian; Wan Azman Wan Ahmad; Rosli Mohd Ali
Journal:  Cardiol J       Date:  2019-09-30       Impact factor: 2.737

Review 2.  Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians?

Authors:  Doreen Tan Su-Yin
Journal:  Eur Cardiol       Date:  2018-12

3.  The outcomes of reperfusion therapy with streptokinase versus tenecteplase in ST-elevation myocardial infarction (STEMI): a propensity-matched retrospective analysis in an Asian population.

Authors:  Hock Peng Koh; Adyani Md Redzuan; Shamin Mohd Saffian; Jivanraj R Nagarajah; Noel Thomas Ross; Hasnita Hassan
Journal:  Int J Clin Pharm       Date:  2022-03-03

4.  Efficacy and safety of drug-coated balloons in the treatment of de novo coronary lesions in very small vessels: a prospective, multicenter, single-arm trial.

Authors:  Mingduo Zhang; Jingwen Yong; Yuan Zhou; Min Zhang; Xiantao Song; Shubin Qiao; Lefeng Wang; Qian Tong; Li Zhang; Bei Shi
Journal:  Ann Transl Med       Date:  2022-04

5.  Incidence of Major Bleeding in Patients with Pulmonary Thromboembolism Treated with Fixed Dose Alteplase 100 mg.

Authors:  Dae Hwan Bae; Won Jae Lee; Yoon Mi Shin
Journal:  J Korean Med Sci       Date:  2020-08-24       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.